MYC and embryonal neoplasm: Future trials using chemotherapy should really focus on pediatric CNS embryonal tumors known to be chemosensitive but for whom the ideal combination has not yet been identified, specifically MYC-amplified group 3 MB, recurrent MB, and young children with radiation-sparing approaches.